user
menu
letter
Sign InRegister
langEnglisharrow

Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified)

製品番号/仕様
価格
Availability
数量
DDC-H55H6-20ug
$245.00
In Stock - Delivery in 2-3 weeks
DDC-H55H6-500ug
$2,225.00
In Stock - Delivery in 2-3 business days
DDC-H55H6
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
Request Quote
製品詳細
データ表示
Reviews & Citations
Resources
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Aromatic-L-amino-acid decarboxylase, Dopa decarboxilase, AADC

Source

Human DDC, His Tag (DDC-H55H6) is expressed from Baculovirus-Insect cells. It contains AA Met 1 - Glu 480 (Accession # P20711-1).

Predicted N-terminus: Met 1

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 55.8 kDa. The protein migrates as 53-58 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in 25 mM MES, 150 mM NaCl, pH6.0 with glycerol as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 3 months under sterile conditions.
ACRO Quality Management System

バックグランド

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively. DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.